Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial


Winston, Alan, Amin, Janaki, Clarke, Amanda, Else, Laura, Amara, Alieu ORCID: 0000-0002-1137-2948, Owen, Andrew ORCID: 0000-0002-9819-7651, Barber, Tristan, Jessen, Heiko, Avinghsanon, Anchalee, Chetchotisakd, Ploenchan et al (show 4 more authors) (2015) Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial CLINICAL INFECTIOUS DISEASES, 60 (7). pp. 1026-1032. ISSN 1058-4838, 1537-6591

[thumbnail of Clin Infect Dis.-2015-Winston-1026-32.pdf] Text
Clin Infect Dis.-2015-Winston-1026-32.pdf - Unspecified
Access to this file is embargoed until Unspecified.
Download (0B)

Abstract

Background. The optimal penetration of antiretroviral agents into the central nervous system may be a balance between providing adequate drug exposure to inhibit human immunodeficiency virus (HIV) replication while avoiding concentrations associated with neuronal toxicities. Methods. Cerebrospinal fluid (CSF) exposure of efavirenz and the metabolites 7-hydroxy (7OH) and 8-hydroxy (8OH) efavirenz were assessed after at least 12 weeks of therapy in HIV-infected subjects randomized to commence antiretroviral regimens containing efavirenz at either 400 mg or 600 mg once daily. Results. Of 28 subjects (14 and 14 on efavirenz 400 mg and 600 mg, respectively), CSF HIV RNA was undetectable in all. Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with 90% confidence intervals [CIs]) for the 400-mg and 600-mg dosing groups were 16.5 (13-21) and 19.5 (15-25) ng/mL; 0.6 (.4-.9) and 0.6 (.4-1) ng/mL; and 5.1 (4.0-6.4) and 3.1 (2.1-4.4) ng/mL, respectively. Efavirenz concentration in CSF was >0.51 ng/mL (proposed CSF 50% maximal inhibitory concentration for wild-type virus) in all subjects, and 8OH-efavirenz concentration in CSF was >3.3 ng/mL (a proposed toxicity threshold) in 11 of 14 and 7 of 14 subjects randomized to the 400 mg and 600 mg doses of efavirenz, respectively. Whereas CSF efavirenz concentration was significantly associated with plasma concentration (P <. 001) and cytochrome P450 2B6 genotype (CSF efavirenz GG to GT/TT geometric mean ratio, 0.56 [90% CI,. 42-.74]), CSF 8OH-efavirenz concentration was not (P =. 242 for association and CSF 8OH-efavirenz GG to GT/TT geometric mean ratio, 1.52 [90% CI,. 97-2.36]). Conclusions. With both doses of efavirenz studied, CSF concentrations were considered adequate to inhibit HIV replication, although concentrations of 8OH-efavirenz were greater than those reportedly associated with neuronal toxicity. CSF exposure of 8OH-efavirenz was not dependent on plasma exposure and, as we postulate, may be subject to saturable pharmacokinetic effects.

Item Type: Article
Uncontrolled Keywords: efavirenz, pharmacokinetics, pharmacogenomics, CSF, HIV
Subjects: ?? RM ??
Depositing User: Symplectic Admin
Date Deposited: 21 May 2015 15:53
Last Modified: 16 Jun 2026 12:10
DOI: 10.1093/cid/ciu976
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/2011747
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.
Altmetric
CORE (COnnecting REpositories)